Cardiovascular Toxicity and Immune Checkpoint Inhibitors

<p>Cardiovascular Toxicity and Immune Checkpoint Inhibitors</p> <p>Guest: Joerg Herrmann, M.D. (<a href='https://twitter.com/mayocvonc'>@mayocvonc</a>)</p> <p>Host: Malcolm R. Bell, M.D. </p> <p>Immune checkpoints are integral to the immune system, ensuring that there is no overactivation once an immune response is triggered. Seven immune checkpoint inhibitors — which interfere with that natural brake in the immune system — are currently approved for use in cancer treatment. The immune checkpoint inhibitors unleash T cells to attack a tumor, with dramatic results.</p> <p>Joining us today to discuss immune checkpoint inhibitors and cardiovascular toxicity is Joerg Herrmann, M.D., director of the Cardio-Oncology Clinic at Mayo Clinic in Rochester, Minnesota.</p> <p>Specific topics discussed:</p> <ul><li>Explanation and applications of immune checkpoint inhibitors</li> <li>Types of malignancies treated with T cell-based therapies and their outcomes</li> <li>Related cardiac toxicities and how to diagnose them</li> <li>Evaluation in the outpatient setting</li> </ul> <p>Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at <a href='https://cveducation.mayo.edu'>https://cveducation.mayo.edu</a> or on Twitter <a href='https://www.twitter.com/mayocliniccv'>@MayoClinicCV</a>.</p> <p>No CME credit offered for this episode.</p> <p>Podcast episode transcript found <a href='https://mcdn.podbean.com/mf/web/q6m96p/P-MayoCV13_Cardiovascular_Toxicity_Immune_Checkpoint_Inhibitors_Bell-Herrmann_CC_Transcript8kxsd.pdf'>here</a>.</p>